For more information or to sign up for a trial
please contact our Clinical Trials Team:
(909) 478-7973
Trials by Tumor Types:
Breast Cancer Trials:
No Active Trials
back to top ↑
Colon Cancer Trials:
No Active Trials
back to top ↑
Lung Cancer Trials:
Lung - NCT06228326
Protocol KB707-02
KB707-02: A Phase 1/2 Study of Inhaled KB707 in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs (KYANITE-1)
OPEN to enrollment
Lung - NCT05671510
Protocol PRESERVE-003
Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)
Open to Enrollment
Lung - NCT06692738
Protocol D702BC00001
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02)
Open to Enrollment
Lung - NCT06627647
Protocol D702FC00001
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)
Open to Enrollment
Lung - NCT05785767
Protocol R3767-ONC-2235
A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%
active - closed to enrollment
Lung - NCT05800015
Protocol R3767-ONC-2236
A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression Levels
active - closed to enrollment
Prostate Cancer Trials:
No Active Trials
back to top ↑
Malignant Melanoma Trials:
Melanoma - NCT06246916
Protocol - R3767-ONC-22122
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Open to Enrollment
Multiple Myeloma Trials:
No Active Trials
back to top ↑
Non-Hodgkin Lymphoma Trials:
Non-Hodgkin Lymphoma - NCT04384484
Protocol ADCT-402-311
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS 5)
active - Closed to enrollment
Hematologic Malignancies Trials:
Hematologic - NCT04384484
Protocol ADCT-402-311
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS 5)
active - Closed to enrollment
Hematologic - NCT05490446
Protocol AG946-C-002
A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Double-blind, Randomized, Placebo-Controlled (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes
active - Closed to enrollment
Hematologic - NCT06093672
Protocol DSC 08-2357-32
Randomized, Open-label, Multicenter Phase 3 Study to Assess the Efficacy and Safety of GIVinostat Versus Hydroxyurea IN JAK2V617F-positive High-risk Polycythemia Vera Patients: the GIV-IN PV TRIAL
open to enrollment
Other Trials:
Other - NCT05366881
cfMeDIP-seq Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease (CAMPERR)
active - Closed to enrollment
Other - NCT04384484
Protocol ADCT-402-311
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS 5)
active - Closed to enrollment
For more information or to sign up for a trial
please contact our Clinical Trials Team:
(909) 478-7973
Trials Pending Site Activation:
Other - NCT (pending)
Protocol R7508-CAT-2392
A PHASE 3 MULTICENTER, RANDOMIZED DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF REGN7508, A MONOCLONAL ANTIBODY AGAINST FXI, FOR PRIMARY PROPHYLAXIS OF CANCER-ASSOCIATED THROMBOSIS FOR PARTICIPANTS WITH SOLID TUMORS UNDERGOING CANCER TREATMENT (ROXI-CAT-I)
PeNDING SITE ACTIVATION
Other - NCT (pending)
Protocol R7508-CAT-2396
A multicenter, randomized, open label, active comparator-controlled phase 3 study to assess efficacy and safety of REGN7508, a monoclonal antibody against FXI, for the treatment and secondary prevention of symptomatic VTE in participants with solid and hematologic cancers”
(ROXI CAT II)
